内容紹介
Two Cases in Which Eribulin Mesylate Was Effective for Taxane-Resistant Advanced Breast Cancer
Summary
We experienced 2 cases in which eribulin mesylate was effective for taxane-resistant advanced breast cancer. Case 1: A 65-year-old woman was diagnosed with advanced breast cancer(T4cN2aM0, stageⅢB)and treated with chemotherapy(nab-paclitaxel). Bone metastasis was observed; then, she sequentially received epirubicin and cyclophosphamide, nab-paclitaxel, and bevacizumab and paclitaxel. However, lung metastases appeared, and we changed the regimen to eribulin mesylate. We administered 11 courses of eribulin mesylate before bone marrow metastasis appeared. Eribulin mesylate was effective for more than 1 year. Case 2: A 77-year-old woman was diagnosed with advanced breast cancer(T4bN3cM1, stageⅣ), and liver and pleural metastasis were observed during an examination at the first visit. Four courses of nab-paclitaxel were administered, but because of the increase in pleural effusion, we changed the regimen to eribulin mesylate. Thirteen courses of eribulin mesylate were administered before the disease progressed. The progression-free survival was 9.53 months. Through the 2 cases in which eribulin mesylate was effective for taxane-resistant advanced breast cancer, the effect of eribulin mesylate compared to taxane was clinically inferred. Key words: Breast cancer, Chemotherapy, Eribulin mesylate
要旨
タキサン系薬剤抵抗性進行乳癌に対しエリブリン投与が効果的であった2症例を経験した。症例1: 患者は65歳,女性。局所進行乳癌T4cN2aM0,stageⅢBに対し,nab-paclitaxel(nab-PTX)にて化学療法を開始した。骨転移の出現を認め,EC(epirubicin+cyclophosphamide),nab-PTX,bevacizumab(BV)+paclitaxel(PTX)を順次投与するも局所進行および肺転移の出現を認め,エリブリンへ変更した。骨髄転移が出現しPDとなるまでにエリブリンを11コース施行し,long SDを維持した。症例2: 患者は77歳,女性。進行乳癌T4bN3cM1,stageⅣに対し,nab-PTXにて化学療法を開始した。胸水の増加を認め,エリブリンへ変更した。PDとなるまでにエリブリンを13コース施行し,無増悪生存期間は9.53か月であった。タキサン系薬剤抵抗性進行乳癌に対しエリブリン投与が効果的であった2症例を通じて,タキサン系薬剤とは異なるエリブリンの作用が臨床的に推察された。
目次
Summary
We experienced 2 cases in which eribulin mesylate was effective for taxane-resistant advanced breast cancer. Case 1: A 65-year-old woman was diagnosed with advanced breast cancer(T4cN2aM0, stageⅢB)and treated with chemotherapy(nab-paclitaxel). Bone metastasis was observed; then, she sequentially received epirubicin and cyclophosphamide, nab-paclitaxel, and bevacizumab and paclitaxel. However, lung metastases appeared, and we changed the regimen to eribulin mesylate. We administered 11 courses of eribulin mesylate before bone marrow metastasis appeared. Eribulin mesylate was effective for more than 1 year. Case 2: A 77-year-old woman was diagnosed with advanced breast cancer(T4bN3cM1, stageⅣ), and liver and pleural metastasis were observed during an examination at the first visit. Four courses of nab-paclitaxel were administered, but because of the increase in pleural effusion, we changed the regimen to eribulin mesylate. Thirteen courses of eribulin mesylate were administered before the disease progressed. The progression-free survival was 9.53 months. Through the 2 cases in which eribulin mesylate was effective for taxane-resistant advanced breast cancer, the effect of eribulin mesylate compared to taxane was clinically inferred. Key words: Breast cancer, Chemotherapy, Eribulin mesylate
要旨
タキサン系薬剤抵抗性進行乳癌に対しエリブリン投与が効果的であった2症例を経験した。症例1: 患者は65歳,女性。局所進行乳癌T4cN2aM0,stageⅢBに対し,nab-paclitaxel(nab-PTX)にて化学療法を開始した。骨転移の出現を認め,EC(epirubicin+cyclophosphamide),nab-PTX,bevacizumab(BV)+paclitaxel(PTX)を順次投与するも局所進行および肺転移の出現を認め,エリブリンへ変更した。骨髄転移が出現しPDとなるまでにエリブリンを11コース施行し,long SDを維持した。症例2: 患者は77歳,女性。進行乳癌T4bN3cM1,stageⅣに対し,nab-PTXにて化学療法を開始した。胸水の増加を認め,エリブリンへ変更した。PDとなるまでにエリブリンを13コース施行し,無増悪生存期間は9.53か月であった。タキサン系薬剤抵抗性進行乳癌に対しエリブリン投与が効果的であった2症例を通じて,タキサン系薬剤とは異なるエリブリンの作用が臨床的に推察された。